{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:27:37Z","timestamp":1776014857424,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00876-w","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T07:03:03Z","timestamp":1687762983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-6604","authenticated-orcid":false,"given":"Steven M.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Haberberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Galeotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Ramkissoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9310-5773","authenticated-orcid":false,"given":"Daniel R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew C.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1514","authenticated-orcid":false,"given":"Joshua F.","family":"Zeidner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi L.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan D.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"876_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s43018-021-00199-4","volume":"2","author":"L Wang","year":"2021","unstructured":"Wang L, Birch NW, Zhao Z, Nestler CM, Kazmer A, Shilati A, et al. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia. Nat Cancer. 2021;2:515\u201326.","journal-title":"Nat Cancer"},{"key":"876_CR2","doi-asserted-by":"publisher","first-page":"e1601602","DOI":"10.1126\/sciadv.1601602","volume":"3","author":"Z Li","year":"2017","unstructured":"Li Z, Zhang P, Yan A, Guo Z, Ban Y, Li J, et al. ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis. Sci Adv. 2017;3:e1601602.","journal-title":"Sci Adv"},{"key":"876_CR3","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","volume":"127","author":"J He","year":"2016","unstructured":"He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, et al. Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016;127:3004\u201314.","journal-title":"Blood"},{"key":"876_CR4","doi-asserted-by":"publisher","first-page":"26417","DOI":"10.18632\/oncotarget.25443","volume":"9","author":"K Tarlock","year":"2018","unstructured":"Tarlock K, Zhong S, He Y, Ries R, Severson E, Bailey M, et al. Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. Oncotarget. 2018;9:26417\u201330.","journal-title":"Oncotarget"},{"key":"876_CR5","unstructured":"Catalogue of Somatic Mutations in Cancer [Internet]. United Kingdom: Wellcome Sanger Institute; c1992-present [cited 2021 May 17]. Available from: https:\/\/cancer.sanger.ac.uk\/cosmic. 2021:2021."},{"key":"876_CR6","doi-asserted-by":"publisher","unstructured":"Scarpa FJ, Paul M, Wolfson WA, Weiss LM, Funari VA, Blocker F. STAG2-mutated AML patients: ASXL1 cohesin binding motif status and mutation landscape. J Clin Oncol. 2020;38:7538\u201338. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.7538","DOI":"10.1200\/JCO.2020.38.15_suppl.7538"},{"key":"876_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-05085-9","volume":"9","author":"S Asada","year":"2018","unstructured":"Asada S, Goyama S, Inoue D, Shikata S, Takeda R, Fukushima T, et al. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nat Commun. 2018;9:1\u201318.","journal-title":"Nat Commun"},{"key":"876_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29142-6","volume":"13","author":"M Binder","year":"2022","unstructured":"Binder M, Carr RM, Lasho TL, Finke CM, Mangaonka AA, Pin CL, et al. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. Nat Commun. 2022;13:1434.","journal-title":"Nat Commun"},{"key":"876_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0025-8","volume":"7","author":"CK Yannakou","year":"2017","unstructured":"Yannakou CK, Jones K, McBean M, Thompson ER, Ryland GL, Doig K, et al. ASXL1 c.1934dup;p.Gly646Trpfs*12\u2014a true somatic alteration requiring a new approach. Blood Cancer J. 2017;7:656.","journal-title":"Blood Cancer J"},{"key":"876_CR10","doi-asserted-by":"publisher","first-page":"e0204218","DOI":"10.1371\/journal.pone.0204218","volume":"13","author":"S Montes-Moreno","year":"2018","unstructured":"Montes-Moreno S, Routbort MJ, Lohman EJ, Barkoh BA, Kanagal-Shamanna R, Bueso-Ramos CE, et al. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS ONE. 2018;13:e0204218.","journal-title":"PLoS ONE"},{"key":"876_CR11","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1182\/blood-2011-08-368225","volume":"118","author":"KH Metzeler","year":"2011","unstructured":"Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlchsmidt J, Mrozek K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118:6920\u201329.","journal-title":"Blood"},{"key":"876_CR12","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1182\/blood.2018879536","volume":"133","author":"G Rotunno","year":"2019","unstructured":"Rotunno G, Mannarelli C, Brogi G, Pacilli A, Gesullo F, Mannelli F, et al. Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs\u221712 mutation. Blood. 2019;133:2802\u201308.","journal-title":"Blood"},{"key":"876_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/leu.2017.318","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Lasho TL, Finke C, Gangat N, Hanson CA, Ketterling RP, et al. Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis. Leukemia. 2018;32:837\u20139.","journal-title":"Leukemia"},{"key":"876_CR14","first-page":"2152","volume":"41","author":"N Tsuboyama","year":"2022","unstructured":"Tsuboyama N, Wang R, Szczepanski AP, Chen H, Zhao Z, Shi L, et al. Therapeutic targeting of BAP1\/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer. Oncogene 2022 4115. 2022;41:2152\u201362.","journal-title":"Oncogene 2022 4115"},{"key":"876_CR15","doi-asserted-by":"publisher","first-page":"e142149","DOI":"10.1172\/jci.insight.142149","volume":"6","author":"Z Tothova","year":"2021","unstructured":"Tothova Z, Valton AL, Gorelov RA, Vallurupalli M, Krill-Burger JM, Holmes A, et al. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS\/AML. JCI insight. 2021;6:e142149.","journal-title":"JCI insight"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00876-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00876-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00876-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T07:03:11Z","timestamp":1687762991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00876-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00876-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"29 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JH and NF are employed by Foundation Medicine, Inc. All other authors declare no relevant competing financial interests. The authors received no specific funding for this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}